In Initial Assessments, NICE Recommends Celgene's Thalidomide And J&J's Bortezomib
This article was originally published in The Pink Sheet Daily
Executive Summary
Thalidomide and bortezomib could be recommended for in multiple myeloma, but NICE rejects Novartis' Xolair for children with severe allergic asthma.